Close Menu

NEW YORK – Bruker said today it has completed debt financing with which it aims to add to its financial flexibility and fund corporate strategic objectives.

The company said the move takes advantage of low interest rates in the US and Europe while fixing rates on roughly 60 percent of its borrowing capacity and extending debt maturities to 2026 and 2029.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.